Benchmark Holdings appoints Peter George as chairman
AIM-listed biotech company Benchmark Holdings has appointed Peter George as chairman with immediate effect, replacing Alex Hambro, whose retirement was announced back in January.
Benchmark Holdings
36.95p
08:04 15/11/24
FTSE AIM 100
3,528.04
15:45 15/11/24
FTSE AIM All-Share
728.67
15:45 15/11/24
Pharmaceuticals & Biotechnology
19,259.77
15:45 15/11/24
Benchmark said George is best known for his achievements as chief executive of global pharmaceutical and services company Clinigen, which he founded in 2010 and grew into close to a £1bn market cap company.
He currently serves as chairman of AIM-listed clinical research provider Ergomed and is also an entrepreneur in residence at Oxford Science Innovations.
CEO Malcolm Pye said: "I am delighted to welcome Peter George to our board as chairman. He has a wealth of experience and a demonstrable track record in delivering shareholder value. I look forward to working closely with him as we continue to drive growth across our organisation."
Prior to Clinigen, George held a number of senior roles in the pharmaceutical and healthcare sectors, including CEO of Penn Pharmaceutical Services. He also co-created Unilabs Clinical Trials International in 1997, which was sold to Icon in 2000.
At 1520 BST, the shares were down 2.9% to 51p.